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Abstract
Parkinson’s Disease is a neurodegenerative disease that is caused by a lack of dopamine.
This lack of dopamine has many effects on a person’s body who has Parkinson’s Disease
including loss of motor control, slowed movement (bradykinesia), changes in speech, impaired
posture and balance, and muscle rigidity. The object of this paper is to explore some of the many
different options for treatment of symptoms of Parkinson’s Disease that are currently available.
There is not one over-arching treatment that can alleviate the symptoms that are caused by
Parkinson’s Disease. However, if multiple treatments are used together, a patient who is
diagnosed with Parkinson’s Disease can live their life with not as strong symptoms and are able
to regain their freedom that this disease has taken from them.
One sentence summary: This paper explores a few of the many different pharmacological and
non-pharmacological treatment options for Parkinson’s Disease.
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Causes of Parkinson’s Disease
Parkinson’s Disease is an increasingly common neurodegenerative disease that currently
has no cure. It is very common in cases where Parkinson’s has been diagnosed to see
depigmentation of the substantia nigra. This depigmentation is thought to be present due to the
progressive and degenerative loss of dopaminergic neurons and receptors. In this depigmented
substantia nigra, there also seems to be the presence of intraneuronal inclusions called Lewy
bodies.1 These Lewy bodies are commonly found in the surviving neurons that haven’t been
degraded yet. Lewy bodies are enriched in one of the main genes thought to be the cause of
Parkinson’s, α-synuclein, as well as many other proteins that have been ubiquitinated and await
destruction.2 Due to the mutations in these genes and other accompanying manifestations, about
50% of the neurons in the substantia nigra are degraded and rendered useless. This causes a
depletion of dopamine within the striatum, which leads to a loss of control of the motor circuits
of the body, resulting in the clinical causes of Parkinson’s that are most common in someone
who is afflicted. The clinical signs that are most common in someone who has Parkinson’s
Disease is muscular rigidity, slowness of movement, postural instability, and the most famous

Figure 1. Different genes and their suggested relationships to Parkinson’s Disease.
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one, the resting tremor. Through research and diagnostic testing, it has been found that there are
multiple potential causes for someone being diagnosed with Parkinson’s. Most cases are thought
to be sporadic, but there are multiple genes that have been targeted for study that when mutated,
give rise to common and familial forms of Parkinson’s. The main genes that are currently being
focused on are α-synuclein (SNCA), parkin, leucine-rich repeat kinase 2 (LRRK2), PTENinduced putative kinase 1 (PINK1), and DJ-1.3 Figure 1 above shows the different genes that
could have a relationship with causing Parkinson’s Disease, their suggested functions, and
reasons they are thought to be the causes for Parkinson’s Disease. SNCA and LRRK2 both are
autosomal dominant genes that are thought to be causes of this disease.4 They are thought to be
affected through a gain-of-function mutation or a dominant negative effect mutation on the
protein.5 Parkin, PINK1, and DJ-1 are all
autosomal recessive genes that when
mutated, can have different functions then
normal and can cause some of the effects
that lead to Parkinson’s Disease.6 Figure 2 to
the left is a concept map of how these
different genes and proteins all link together
and how their functions all can depend on
Figure 2. Concept map of how different genes related to Parkinson's
disease interact.

each other. While each case of Parkinson’s

is different, being able to narrow to the exact cause of why someone is afflicted with this disease
is key in being able to treat this disease. There are different treatment options available for
people diagnosed with Parkinson’s Disease, some medicinal and some non-medicinal. Different
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routes of treatment, pharmacological and non-pharmacological, for Parkinson’s Disease, will be
discussed in this paper.
Current Parkinson’s Disease Treatment Options – Non-Pharmacological
Parkinson’s Disease is a crippling neurodegenerative disease that affects many aspects of
day to day life. While there are treatments to help aid with the symptoms that accompany this
disease, there is no cure for Parkinson’s at this current time. However, there are a few different
routes of treatment that patients can explore to help slow down the degeneration of motor skills
and can help people living with Parkinson’s Disease. Montgomery claims in his review of
rehabilitative approaches to Parkinson’s that there are multiple avenues and therapy options for
people dealing with Parkinson’s, such as physical therapy, occupational therapy, and speech
therapy.7 He also says that these therapy options are hopefully being used to directly modify the
physiological processes in the brain, so people dealing with Parkinson’s can overcome the
symptoms that Parkinson’s causes. In one research article, one of the biggest therapy strategies
that Montgomery talks about is helping people with Parkinson’s manage their symptoms using
neurophysiological support. Using this kind of support can help patients conceptualize their
difficulties and alter their expectations to be able to achieve more reasonable goals and to relearn
how to do basic tasks, if needed.7
Movement impairments related to Parkinson’s Disease are especially difficult for almost
all patients that are showing symptoms. Some of these movement impairments relate to
maintaining balance while standing, losing postural stability, difficulty doing simple tasks that
affect daily living, and frequent falls. While some of the motor ailments of Parkinson’s can be
treated medicinally, not all of them can be treated using drugs. There are other ways to help treat
this disease and one of them is physical activity. Physical activity has been shown to slow down

7

the deterioration of motor functions in the body and help to prolong functional independence.8
Even after the introduction of drugs such as Levodopa, which is primarily used to treat
Parkinson’s Disease, many doctors believed that if paired with physical activity, can help
maximize the benefits of the medication.9
One of the biggest non-medicinal treatment options for people with Parkinson’s is
physical therapy. In physical therapy for Parkinson’s patients, one of the most basic styles of
therapy is amplitude training. According to the John Hopkins Medicine official website, during
this kind of physical therapy, a specific form of physical therapy called LSVT training is used.
LSVT BIG stands for Lee Silverman Voice Treatment, and BIG stands for big movements. In
this treatment option, patients make large and overexaggerated physical movements based on
what their physical therapist says, like swinging their arms or taking really high steps. Doing
these overexaggerated movements is thought to help retrain the muscle to do basic movements
and to help slow down the progression of hypokinesia.10 Another form of physical therapy that
can help people with Parkinson’s feel more confident with living day-to-day is reciprocal pattern
therapy. This form of therapy is thought to help reinforce just basic movements that become hard
or impossible with Parkinson’s. Some of these reciprocal behaviors are sometimes as simple as
swinging the arms when walking or taking basic steps in front of one another while walking.
Doing these simple behaviors over and over is thought to relearn the basic movements and
ingrain how to do them while dealing with the symptoms of Parkinson’s.10 One aspect of life that
Parkinson’s Disease disrupts is normal balance. The disruption of balance in everyday life can
have a major impact on people with Parkinson’s. Balance is a combination of visual feedback
from a certain stimulus, the balancing system in the inner ear reacting to said stimulus, and then
the brain interpreting these two feedback mechanisms together. Balance therapy has shown in
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different studies to be an
exceptional tool for people with
Parkinson’s and in turn, helping the
patients regain their confidence in
living with their condition. In this
therapy style, practice balancing
and walking in straight lines is
done. During these therapy
sessions, the patient is taught how
to compensate for changes in their
balance.10 Studies have shown that
patients who use this type of
physical therapy have increased
confidence in preforming simple
tasks, such as walking and sitting in
a chair, which can help the patient
Figure 3. Data from Tai-Chi study at baseline and six months for the different
groups.

to be more secure living with this

disease. One unique way that people with Parkinson’s Disease can help keep their balance and
posture strong is to engage in Tai Chi! In a study published in the New England Journal of
Medicine, Tai Chi was shown to “improve strength, balance, physical function, and to prevent
falls in older adults”.11 In the Tai-Chi study, there were 3 groups of participants. All participants
of the trial had Parkinson’s Disease. They were broken up into different groups; one group that
would be participating in Tai Chi for their physical activity/therapy, one group that would be
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doing Resistance training, and the last group that would be doing Stretching. Tai Chi was found
to help reduce balance impairments, as well as add additional benefits to improved functional
capacity and reduced falls, when compared to the other groups.11 Figure 3 above shows data and
statistics for the three different trial groups. For most of the data, there seems to be a significant
difference between Tai Chi and Resistance groups for some changes from the baseline in
maximum excursion, directional control, and stride length. However, there is a significant
difference between Tai Chi and Stretching groups in every category in the table. The significant
difference between the Tai Chi group data and the Resistance and Stretching group data showed
that Tai Chi was more effective at treating and empowering different basic functions for people
dealing with Parkinson’s. One of the biggest problems with Parkinson’s Disease is a patient
being unable to
control their
motor movements
and falling, which
can cause
significant
Figure 4. Data from Tai-Chi study regarding the amount of falls each group had during the study.

damage. Falling is

a significant part of dealing and living with Parkinson’s due to the affected individual’s balance
being diminished. One of the purposes of this research study was to look at the adverse effects of
daily living and falls that participants were involved in, depending on what group of they were
in. Figure 4 above shows data collected from participants regarding how many total falls they
had while participating in this study. This data shows that the group that participated in Tai Chi
had a significantly lower number of falls than the participants in the Resistance group and the
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Stretching group. Focusing on more strenuous physical therapy options, if the patient is able to,
that help to reduce the number of falls and relieve other negative side effects in the life of
someone with Parkinson’s might be a key non-medicinal treatment route. This study’s results
show that there are many unique and different ways for people living with Parkinson’s to
strengthen their motor control, even though they have a degenerative disease. One final physical
therapy strategy that is good for people living with Parkinson’s is basic strength training. While
muscles weaken naturally as someone gets older, these effects are multiplied in patients with
Parkinson’s. Doing strength training such as resistance exercises with light dumbbells or a
resistance band can help the patient maintain positive motor control over their muscles. Poolbased strength training classes are also great for people living with Parkinson’s because it helps
to take the excess force off of joints and muscles, while also training and using them in an
efficient manner.10
One of the most important parts of battling with any disease is the mental and
physiological aspect. If someone is diagnosed with a disease or a condition and they are defeated
in their minds and they have no hope of ever getting better, then the disease has already won.12
However, if the person that was diagnosed stays positive about their outcome and truly believes
they can beat their condition, then their outlook on life and dealing with treatment stays high.
Many diseases and conditions have support groups where people who are afflicted by said
disease or condition, can go and talk to and support one another, and Parkinson’s Disease is no
different. Parkinson’s Disease is a crippling disease that deteriorates their physical and mental
condition. People with Parkinson’s will eventually lose their ability to live life on their own and
will no longer be able to control their lives or bodies. However, it has been shown that when
patients have access to professional or member-led support groups, the acceptance for the disease
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goes up and patients are better able to cope with its challenges.12 Support groups of any kind are
also another important part of therapy and learning to live with the disease. Online support
groups are becoming ever more popular with recent technological advancements.13 Online
support groups also help people with Parkinson’s because it gives them easy access to help and
support, without having to leave the comfort of their home.14 In Attard’s journal, she looked at
how accessing support forums and groups can have a positive impact on people dealing with
disease, especially Parkinson’s Disease. On these forums and online support groups, people were
able to offer much valued support and advice, especially during times of crisis or great emotional
distress. One quote from the forum states that, “the importance of the forums as a source of
support was apparent as members often expressed their gratitude towards other for informing,
encouraging, caring, and thinking of them as they battles with the disease”.12 One strength of
support groups and online forums is that people who have been diagnosed with the disease for a
longer period of time than others can help guide and share experiences with people who have
been recently diagnose. Attard stated that sharing personal stories was an integral part of the
support groups and forums. The forums and groups also allowed people to stay connected and up
to date on interesting and useful information, as well as keeping up with the latest advances in
medication/treatment. One of the most important parts of support groups and online forums is
helping an inflicted individual see that they are not alone in their fight. Attard states that new
members to the online forum often felt relief when they finally realized that there were other
people struggling with the same day to day experiences that they were and that they were not
alone. One final important note about support groups and online forums is that they are an
incredible tool to help people with that disease to stay encouraged and have positive thinking.15
Attard states that a number of members would post on the online forum about how they were
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determined to live a full life and not let their disease or illness dominate their lives.. Being able
to gain insight from others and to have support on the bad days is just as important as important
as keeping up with a physical therapy regiment. Mental/emotional therapy can help to strengthen
the mind and keep the spirts up while dealing with a debilitating disease.16

Current Parkinson’s Disease Treatment Options – Pharmacological
Being able to relieve some of the effects of degenerative diseases is key for patients to be
able to live a mostly normal life. Drugs that can inhibit certain receptors, make missing
substances out of precursors, and slow down the negative effects of a disease are all important.
Most disease have some sort of medical treatment available and Parkinson’s Disease is no
different. One of the most famous drugs used to treat Parkinson’s is Levodopa. In Parkinson’s
Disease, the cause of the symptoms is due to a decrease in dopamine production.17 More
specifically, degradation of the substantia nigra occurs and this leads to massive disruption in the
brain’s nigrostriatal pathway. This leads to one of the common signs of Parkinson’s Disease, a
decrease in production of dopamine. Levodopa helps to fill the body’s missing dopamine levels
by administering the precursor so the body can change it into the usable form of dopamine
easily. Levodopa is very efficient because it can cross the blood-brain-barrier, while regular
dopamine cannot. Levodopa is commonly taken with carbidopa, which is a dopamine
decarboxylase inhibitor. The main reason carbidopa is commonly taken along with Levodopa is
because carbidopa can decrease the amount of levodopa that is converted into dopamine in the
periphery, so levodopa can cross the blood-brain-barrier and be more effective. Once levodopa
has crossed the blood-brain-barrier, it is converted into dopamine. This dopamine that is
produced helps to activate postsynaptic dopaminergic receptors in the brain, which help to
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compensate for the natural decreased dopamine production.18 It is most commonly used to treat
Parkinson’s and is usually prescribed once the patient’s symptoms become too severe.
Even as powerful as a drug that Levodopa is, its bioavailability is something to be
concerned about. Its bioavailability when taken orally is only around 30%.19 There has been
thought that other methods of delivery of this dopamine precursor should be considered. One
other route that is being explored is delivering Levodopa via an intranasal injection with
nanoparticles. With this route, it is thought to bypass the blood-brain-barrier and peripheral
metabolism totally, being delivered to the brain via the olfactory and trigeminal nerve
pathways.20 Even though this current route of treatment is thought to be more effective and easier
to administer, it is still in the experimental phase, but it has shown promising results.19,20
Other than dopamine precursors, there exists another kind of drug used to treat
Parkinson’s Disease called dopamine agonists. There are currently 10 dopamine agonists that are
marketed for the treatment of Parkinson’s. Five of these dopamine agonists are ergot derivatives,
meaning they are derived from a fungus that produces alkaloids called ergotamines. These 5
drugs are bromocriptine, cabergoline, dihydroergocryptine, lisuride, and pergolide. The other 5
dopamine agonists are non-ergot derivatives, and they are apomorphine, piribedil, pramipexole,
ropinirole, and rotigotine.25 The most popular choice among these dopamine precursors is
pramipexole. When discussing medicinal treatments for Parkinson’s Disease, it is important to
understand that different drugs may have different impacts on different people. There is not one
single treatment option that covers all angles of Parkinson’s, and most times, multiple of these
drugs are used together to help treat symptoms. It is important to look at each patient as an
individual and to devise the proper treatment plan for them, and not go off of what worked in the
treatment of someone else.
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One commonly seen drug that is used to treatment the symptoms of Parkinson’s Disease
is Pramipexole. Even though Levodopa is seen as the “golden standard” drug for treating
Parkinson’s, in recent years, its effectiveness has faded quickly for some patients and it has been
known to cause extreme motor fluctuations as well.21 Pramipexole is a dopamine agonist, unlike
levodopa, which is a dopamine precursor. Pramipexole is a non-ergot D2/D3 synthetic
aminobenzothiazole derivative that is found to be an effective monotherapy is patients that have
been recently diagnosed with Parkinson’s Disease.22 Pramipexole, when taken, has selective
affinity and action at dopamine receptors in the brain that belong to the D2 subfamily. When
pramipexole is bound to these receptors, it is seen to have full activity similar to if sufficient
levels of dopamine were present. With this specific drug activating dopamine receptors, instead
of making dopamine like levodopa, it has shown been shown to not cause as severe muscle and
motor fluctuations in patients.23 One other dopamine agonist that has seen wide usage to treat
Parkinson’s Disease is ropinirole. Ropinirole was widely accepted as a transdermal patch
delivery to help treat early Parkinson’s, but it has been withdrawn from the US markets, due to
the drug crystalizing in the patch.24
In the table below, there is a comparison for levodopa vs dopamine agonists in the
treatment for Parkinson’s Disease. While both drugs have the potential to show possible
neurotoxic or neuroprotective effects in vitro, both drugs have strong evidence of no neurotoxic
or neuroprotective effects in patients with Parkinson’s disease.26 Levodopa has shown to provide
better motor efficacy in the early years after diagnosis and treatment has begun, but the side
effects of levodopa have been shown to be at an increased level as well. Levodopa is shown to
have more motor fluctuations and have earlier onset dyskinesia than dopamine agonists. While
the dopamine agonists do not have as severe side effects of levodopa, the motor efficacy is lower
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in patients that take this drug over levodopa.27 Overall, both drugs are extremely effective at
improving the quality of life of someone that has Parkinson’s Disease.25

Table 5. Levodopa vs Dopamine Agonists.25

One interesting side effect of Parkinson’s Disease is psychotic symptoms that become
prevalent due to the continuum of Parkinson’s Disease progression. The National Institute of
Neurological Disorders and Stroke and National Institute of Mental Health use the term “PD
psychosis” (PDP) to describe these symptoms.28 When dealing with PD psychosis, criteria for a
correct diagnosis of psychosis caused by Parkinson’s Disease must be met. These criteria are: (1)
The presence of at least one of the following symptoms: illusions, false sense of presence,
hallucinations, or delusions; (2) A diagnosis of Parkinson’s Disease before any of the symptoms
started to occur; (3) The symptoms are recurrent or continuous for at least 1 month; (4) The
symptoms aren’t better classified as another mental health disorder such as dementia,
schizophrenia, delusional disorder, and mood disorders.29 PDP may occur partially due to the
medications that a patient is taking to treat their Parkinson’s symptoms. These drugs include
levodopa and dopamine agonists, which were both discussed above. Levodopa and dopamine
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agonists are crucial drugs in helping to treat the symptoms of Parkinson’s Disease and can not
stop being administered. There have been different drug trials to try and find a solutions for these
psychotic symptoms, and one medication has shown strong indications of being able to treat
those symptoms. Pimavanserin, otherwise known as Nuplazid, is an atypical antipsychotic
medication, and is also the first medication that has been approved by the FDA to help treat the
symptoms of hallucinations and delusions associated with Parkinson’s Disease psychosis.30 One
of the main reasons that this specific drug is effective at treating these symptoms is because it
does not have affinity and lacks activity at dopaminergic, muscarinic, adrenergic, and
histaminergic receptors, meaning it does not interact or block the treatment routes of levodopa
and dopamine antagonists. It has also shown to not have any serious adverse side effects and
does not worsen the motor symptoms of Parkinson’s Disease.30

Conclusion
Parkinson’s Disease is a chronic and progressive neurodegenerative disorder that impairs
motor function, presents bradykinesia, rigidity, and postural instability. This paper has explored
different treatment options for patients that are currently available to treat the symptoms of
Parkinson’s Disease. While there is no cure for Parkinson’s, a combination of pharmacological
and non-pharmacological treatment methods is the best way to combat the symptoms that
Parkinson’s Disease shows. There is no one drug or physical therapy method that is the best
option for treatment. Exploring different treatment routes and finding what is best for the patient
should always be desired. I hope this paper has shown that there are different methods to treating
Parkinson’s Disease, and hopefully one day, a cure will be found to rid the world of this disease.
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Potential Future Work With Topic
Parkinson’s Disease is a crippling disease that affects millions of people around the
world, including some of my close and immediate family. In the future, I am planning on going
to medical school and I think it would be very interesting to do research, if possible, for future
drugs to help treat Parkinson’s Disease, or even a cure for it. I plan on continuing my own
research into different treatment methods and looking into up and coming drugs that could help
to end this disease and staying educated on this topic.
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